-
Hinyokika Kiyo. Acta Urologica Japonica Jul 1989A 58-year-old man was admitted to our hospital with the complaint of pollakisuria and micturitional pain. The urine cytology showed malignant cells suggesting the... (Review)
Review
A 58-year-old man was admitted to our hospital with the complaint of pollakisuria and micturitional pain. The urine cytology showed malignant cells suggesting the urothelial cancer, but various examinations could not reveal the malignant lesion. The prostate was also normal by the digital examination, endoscopy, roentgenography, ultrasonography and serum markers, and the transperineal prostate biopsy showed no malignancy. Three years after the first admission the prostate showed slight hardness and the transperineal biopsy suggested adenocarcinoma of the prostate. Hormonal therapy was then started and the prostate showed no remarkable change until about two years later, when rapid progression of the prostatic tumor was recognized. The transperineal biopsy of the prostate revealed the transitional cell carcinoma with negative staining of Alcian-Blue, PAS and PSA (prostate specific antigen). The epithelia of the bladder and posterior urethra were normal. The radical cystoprostatectomy was done and the histological diagnosis was the pure type of primary transitional cell carcinoma of the prostate. The literatures were reviewed and the clinical differentiation between transitional cell carcinoma and adenocarcinoma of the prostate was discussed.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Humans; Male; Methotrexate; Middle Aged; Prostatectomy; Prostatic Neoplasms; Vinblastine
PubMed: 2678986
DOI: No ID Found -
Clinical Drug Investigation Aug 2015Intravesical instillation of glycosaminoglycans is a promising option for the treatment of chronic cystitis, as it supports the regeneration of the damaged urothelial... (Observational Study)
Observational Study
BACKGROUND AND OBJECTIVE
Intravesical instillation of glycosaminoglycans is a promising option for the treatment of chronic cystitis, as it supports the regeneration of the damaged urothelial layer. We investigated the efficacy of short-term intravesical chondroitin sulphate treatment (six courses of instillation) in patients with chronic radiotherapy- or chemotherapy-associated cystitis.
METHODS
This prospective, observational study included patients with chronic radiotherapy- or chemotherapy-associated cystitis, who received six once-weekly intravesical instillations of 0.2% chondroitin sulphate 40 mL. Every week, patients recorded their symptoms and their benefits and tolerance of treatment, using a self-completed questionnaire.
RESULTS
The study included 16 patients (mean age 68.5 years; 50% male). During the study, a reduction in all evaluated parameters was observed. After one dose of chondroitin sulphate, symptom improvement was observed in 38% of patients, and after the second dose, an additional 31% of patients showed improvement. At week 6, 80% of patients had either improved or were symptom free, and significant improvements in urinary urgency (p = 0.0082), pollakisuria (p = 0.0022), urge frequency (p = 0.0033) and lower abdominal pain (p = 0.0449) were observed. Haematuria, present in 9 of the 16 patients at baseline, was completely resolved in all cases after 6 weeks. The majority of patients (93%) evaluated the tolerance of chondroitin sulphate as 'good' or 'very good'. No treatment-related adverse events were reported.
CONCLUSION
Intravesical administration of chondroitin sulphate was effective for the treatment of radiotherapy- or chemotherapy-associated cystitis. Even short-term treatment appears to be effective in reducing symptoms and improving the quality of life of patients.
Topics: Administration, Intravesical; Aged; Chondroitin Sulfates; Chronic Disease; Cystitis; Female; Humans; Male; Middle Aged; Prospective Studies
PubMed: 26175064
DOI: 10.1007/s40261-015-0306-6 -
Oncology Letters Aug 2017, is a species of scallop and a marine bivalve mollusk. In traditional East Asian medicine, scallop meat is used as a drug for the treatment of diabetes, pollakisuria,...
, is a species of scallop and a marine bivalve mollusk. In traditional East Asian medicine, scallop meat is used as a drug for the treatment of diabetes, pollakisuria, and indigestion. The present study was conducted in order to examine the potential anticancer effects of scallop flesh extract (SE) on MCF-7 human breast cancer cells. An MTT assay was used to evaluate cell viability and flow cytometry was used for the assessment of cell cycle distribution and apoptosis. The alteration in protein expression level was determined by western blot analysis, and the amounts of docosahexaenoic acid and eicosapentaenoic acid in the SE were measured by gas chromatography. SE inhibited the growth of MCF-7 human breast cancer cells in a dose-dependent manner by inducing G0/G1 phase arrest. The cell cycle arrest was associated with the upregulation of p53 and p21, and downregulation of G1 phase-associated cyclin D1/cyclin-dependent kinase (Cdk) 4 and cyclin E1/Cdk 2. In addition, SE-mediated cell cycle arrest was associated with the promotion of apoptosis, as indicated by the expression of apoptosis-associated proteins and changes in nuclear morphology. SE appeared to induce the mitochondrial apoptotic cascade, as indicated by a decreased expression of Bcl-2, activation of Bcl-2 associated X protein, release of cytochrome c, decrease in procaspase-3, and an increase in cleaved-poly (ADP-ribose) polymerase (PARP). Furthermore, the expression levels of Fas-associated via death domain and cleaved caspase-8 were increased in a SE dose-dependent manner. Taken together, these results suggest that the intrinsic and extrinsic pathways of apoptosis are associated with the anticancer effects of SE on MCF-7 cells. Thus, SE may be a suitable candidate for the treatment and prevention of human breast cancer.
PubMed: 28789443
DOI: 10.3892/ol.2017.6424 -
Hinyokika Kiyo. Acta Urologica Japonica Apr 2010A 64-year-old man was referred to our hospital with chief complaints of gross hematuria and pollakisuria. Cystoscopic examination showed non-papillary broad basis tumor... (Review)
Review
A 64-year-old man was referred to our hospital with chief complaints of gross hematuria and pollakisuria. Cystoscopic examination showed non-papillary broad basis tumor on the left lateral wall involving the left ureteral orifice. Computed tomography (CT) and magnetic resonance imaging revealed left hydronephrosis and urinary bladder tumor which extended outside of the bladder wall. Transurethral biopsy showed grade 3 urothelial carcinoma with glandular differentiation including signet ring cells. Radical cystectomy, left nephrureterectomy and right ureterocutaneostomy were performed. Pathological examination showed urothelial carcinoma; pT3aN0. Lymph node metastasis occurred five months later. Three courses of M-VAC chemotherapy (methotrexate, vinblastine, adriamycin, cisplatin) were done with little effectiveness. Sixteen months after the operation, he complained of anorexia and tenesmus, and CT showed annular thickening of the rectal wall. A fecal diversion was performed, but he died two months later.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Constriction, Pathologic; Cystectomy; Doxorubicin; Fatal Outcome; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Multiple Primary; Rectal Neoplasms; Rectum; Urinary Bladder Neoplasms; Vinblastine
PubMed: 20448448
DOI: No ID Found -
Hinyokika Kiyo. Acta Urologica Japonica Jul 1991This is a report of the thirteenth known case in Japan of emphysematous cystitis. A 70-year-old man visited our hospital because of pollakisuria and macrohematuria on... (Review)
Review
This is a report of the thirteenth known case in Japan of emphysematous cystitis. A 70-year-old man visited our hospital because of pollakisuria and macrohematuria on November 21, 1989. The patient had been known to have familiar amyloid polyneuropathy for the previous 3 years. Urinalysis showed marked hematopyuria. The residual urine was 216 cc, and urine cultures yielded 10,000,000 colonies of Escherichia coli per ml. Laboratory studies revealed systemic inflammatory findings, but no diabetic change. A plain X-ray film of the abdomen and an excretory urogram (DIP) showed small linear and round gas collections in the bladder shadow. A CT scan revealed multiple gas locules within the bladder wall. A diagnosis of emphysematous cystitis was established. The patient was given antibiotics, and there was striking clinical improvement. Histological examination of the endoscopically obtained biopsy specimen of the bladder revealed amyloidosis. We believe that this patient had a cystitis emphysematosa precipitated neurogenic bladder due to amyloid polyneuropathy and amyloidosis of the bladder.
Topics: Aged; Amyloidosis; Cystitis; Emphysema; Humans; Male; Polyneuropathies; Urinary Bladder, Neurogenic
PubMed: 1927781
DOI: No ID Found -
Nihon Hinyokika Gakkai Zasshi. the... May 2000Our purpose of this study was to evaluate the effect of a transdermal estradiol delivery system in postmenopausal women with confirmed pollakisuria and urinary... (Clinical Trial)
Clinical Trial
PURPOSE
Our purpose of this study was to evaluate the effect of a transdermal estradiol delivery system in postmenopausal women with confirmed pollakisuria and urinary incontinence.
PATIENTS AND METHODS
We investigated 10 postmenopausal women, age 54-83 years, with pollakisuria and urinary incontinence but did not show distinct urological and/or neurological abnormalities. In this study, estradiol transdermal therapeutic system (Estraderm TTS 2 mg) alone were administrated for total of 8-week and this is observational, not randomized, blinded or controlled. A clinical evaluation were performed two times at before and after administration.
RESULTS
In seven eligible cases, the severity of urinary incontinence was graded down in almost of them and the therapeutic effect on urinary incontinence was evaluated as "very effective" in 3 cases, "improved" in 2, "slightly improved" in 1 and "no change" in 1, respectively. In three eligible cases, the severity of pollakisuria was no change in all of them.
CONCLUSION
Thus, the estrogen supplement therapy was considered effective for postmenopausal urinary incontinence.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Estradiol; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Postmenopause; Urinary Incontinence
PubMed: 10853331
DOI: 10.5980/jpnjurol1989.91.501 -
Hinyokika Kiyo. Acta Urologica Japonica Mar 1991A cerebral metabolic activator was administered to patients with cerebrovascular dementia to treat urinary incontinence or pollakisuria. The results are of interest as...
A cerebral metabolic activator was administered to patients with cerebrovascular dementia to treat urinary incontinence or pollakisuria. The results are of interest as discussed in this paper. This study was carried out on 35 patients (15 males and 20 females) with cerebrovascular dementia with the chief complaint of incontinence or pollakisuria averaging in age 78.1 years with a range of 65 to 92. The underlying disease was cerebral hemorrhage in 4 cases, cerebral embolism in 21 cases and sequelae of cerebral apoplexy in 10 cases. ADL was assessed in all cases by cerebral CT or MRI and Hasegawa's test, a simple test for dementia. Bladder function was evaluated by determining urodynamic tests (CMG, UFM, UPP) before and after medical treatment. Test drug was bifemelane hydrochloride, a cerebrovascular metabolic activator. It was administered at a dose of 150 mg/day for periods of 2 months or more. As a result, bladder symptoms improved in 16/35 patients (45.7%), and mental symptoms in 21/35 (60%). Urine voiding and holding as bladder functions determined by urodynamics tests were not affected at all. The effect of this drug on bladder symptoms is secondary to improvement of mental symptoms, and its most pronounced clinical effect was on dementia.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Benzhydryl Compounds; Dementia, Vascular; Humans; Polyuria; Urinary Incontinence
PubMed: 2069105
DOI: No ID Found -
Hinyokika Kiyo. Acta Urologica Japonica Feb 1991Two cases of giant hydrocele, having more than 1,000 ml of contents, are presented. The first patient was a 77-year-old man with the complaint of urination difficulty... (Review)
Review
Two cases of giant hydrocele, having more than 1,000 ml of contents, are presented. The first patient was a 77-year-old man with the complaint of urination difficulty and a very swollen left scrotum of three years duration. Mild prostatic hypertrophy, mild renal dysfunction and hypertension were seen during hospitalization. A scrotal puncture gave 2,100 ml of serous fluid. Radical hydrocelectomy and plastic operation for surplus scrotal skin were done, and difficult urination improved markedly. The second patient was a 77-year-old man with the complaint of right scrotal swelling of fifteen years duration. He had developed pollakisuria and urination difficulty three years previously. When he was transferred our hospital on emergency due to engorgement, the diagnosis of giant hydrocele was made. Right orchidectomy was performed because of marked testicular atrophy and old hemorrhagic fluid of 1,200 ml. Urination difficulty and pollakisuria disappeared postoperatively.
Topics: Aged; Humans; Male; Testicular Hydrocele; Urination Disorders
PubMed: 2048501
DOI: No ID Found -
Nihon Hinyokika Gakkai Zasshi. the... Sep 1991Based on the frequency volume chart, 215 patients who complained of pollakisuria were clinically investigated. The subjects were divided into 2 groups: the elderly group... (Comparative Study)
Comparative Study
Based on the frequency volume chart, 215 patients who complained of pollakisuria were clinically investigated. The subjects were divided into 2 groups: the elderly group was composed of 85 patients more than 65 years of age (mean of 72) and the adult group comprised 130 patients less than 64 years old (mean of 47). The elderly group was characterized by the fact that, during nighttime (after sleep), their urinary volume was larger, each voided volume was smaller and the number of voiding was greater than the other group. Clinical analysis of the causes of pollakisuria enabled us to subdivide them into 6 diagnostic categories. Among the elderly patients polyuria during sleep and unstable bladder were prevalent and among adult patients unstable bladder and over hydration were common. Medication was made in 80 patients (37%), while 108 (50%) needed neither medication nor surgery. It is stressed that the frequency volume chart is one of the important diagnostic tools to evaluate the cause of pollakisuria and to select appropriate treatment.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Urination; Urination Disorders
PubMed: 1942704
DOI: 10.5980/jpnjurol1989.82.1446 -
Hinyokika Kiyo. Acta Urologica Japonica Feb 1987The clinical effect of terodiline hydrochloride (TD-758) was studied in 95 patients with nervous pollakisuria or irritative bladder. TD-758 was given per os randomly at... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
The clinical effect of terodiline hydrochloride (TD-758) was studied in 95 patients with nervous pollakisuria or irritative bladder. TD-758 was given per os randomly at a dose of 24 mg or 12 mg once a day for 4 weeks. The symptoms such as urinary frequency, urinary incontinence and sense of residual urine were improved in 74% of the patients taking 24 mg, and in 51% of the patients taking 12 mg. The difference was statistically significant. Side effects such as dry mouth, constipation and heart burn were observed in 15% of the patients in each group and were not serious. The results of this study indicate that TD-758 is useful for these patients and its optimal dosage is 24 mg once a day.
Topics: Administration, Oral; Adolescent; Adult; Aged; Butylamines; Calcium Channel Blockers; Drug Evaluation; Humans; Middle Aged; Polyuria; Urinary Bladder Diseases; Urinary Incontinence
PubMed: 3591595
DOI: No ID Found